Sitagliptin: The First in a New Class of DPP-4 Inhibitors for the Treatment of Type 2 Diabetes
Abstract
Sitagliptin (JANUVIA®) is the first approved DPP-4 inhibitor for the treatment of T2DM and is approved in over 60 countries worldwide. Sitagliptin is a potent, highly selective and fully reversible DPP-4 enzyme inhibitor that was developed to treat T2DM. Sitagliptin is well-absorbed following oral administration, with a half-life of approximately 12 hours, supporting once-daily administration.
Methodology: Metaanalysis of Stialiptin on Type II diabetes mellitus patients.
Result: A single daily dose achieves 24-hour DPP-4 inhibition that peaks within 2 to 4 hours and maintains at least 80% DPP-4 inhibition over the full 24-hour dosing period. Food does not affect the pharmacokinetics, and the drug exhibits low protein binding, with no clinically important drug-drug interactions.
When publishing with Kerala Medicial Journal (KMJ), authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Work includes the material submitted for publication and any other related material submitted to KMJ. In the event that KMJ does not publish said work, the author(s) will be so notified and all rights assigned hereunder will revert to the author(s).
The assignment of rights to KMJ includes but is not expressly limited to rights to edit, publish, reproduce, distribute copies, include in indexes or search databases in print, electronic, or other media, whether or not in use at the time of execution of this agreement.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
The author(s) hereby represents and warrants that they are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, that the work is original, and does not infringe upon any copyright, propriety, or personal right of any third party, and that no part of it nor any work based on substantially similar data has been submitted to another publication.
